Management issues for elderly patients with breast cancer

被引:27
作者
Extermann M. [1 ]
机构
[1] Moffitt Cancer Center, Tampa, FL 33612
关键词
Breast Cancer; Tamoxifen; Docetaxel; Trastuzumab; Clin Oncol;
D O I
10.1007/s11864-004-0048-9
中图分类号
学科分类号
摘要
Fifty percent of breast cancers occur after the age of 65 years and 25% occur after the age of 75 years. Encountering a breast cancer in an older woman is frequent. After years of death of data specific to the elderly, some evidence is beginning to accumulate concerning breast cancer in the older woman. Recent data from mammography studies confirm its effectives in women with 10 years or more of life expectancy (perhaps even 5 years). Epidemiologic and randomized studies demonstrate that a proper surgery and adjuvant treatment can decrease relapse and improve survival in patients older than 80 years. Radiation therapy studies show a decrease in local relapse even in patients older than 70 years. Adjuvant hormonal therapy has essentially the same effectiveness as in younger women. Chemotherapy has a role in patients older than 70 years. Consensus statements, such as the St. Gallen consensus, have dropped the age limit of 70 years from their recommendations. Comorbidity and life expectancy should be taken into account for proper selection of adjuvant treatment. The treatment of metastatic breast cancer has evolved significantly with the introduction of aromatase inhibitors, new chemotherapeutic agents, and targeted biologic agents. New chemotherapeutic agents are as effective as single agents compared to older and more toxic drug combinations. The cumulative result of the introduction of these new agents, at a population level, is a 7.5-month increase in the median survival time of patients with metastatic breast cancer over the past decade. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:161 / 169
页数:8
相关论文
共 61 条
[1]  
Trimble E.L., Carter C.L., Cain D., Et al., Representation of older patients in cancer treatment trials, Cancer, 74, pp. 2208-2214, (1994)
[2]  
Extermann M., Albrand G., Chen H., Et al., Are older French patients as willing as older American patients to undertake chemotherapy?, J. Clin. Oncol., 21, pp. 3214-3219, (2003)
[3]  
Gotzsche P.C., Olsen O., Is screening for breast cancer with mammography justifiable?, Lancet, 355, pp. 129-134, (2000)
[4]  
Nystrom L., Andersson I., Bjurstam N., Et al., Long-term effects of mammography screening: Updated overview of the Swedish randomised trials, Lancet, 359, pp. 909-919, (2002)
[5]  
Miettinen O.S., Henschke C.I., Pasmantier M.W., Et al., Mammographic screening: No reliable supporting evidence?, Lancet, 359, pp. 404-405, (2002)
[6]  
McPherson C.P., Swenson K.W., Lee M.W., The effects of mammographic detection and comorbidity on the survival of older women with breast cancer, J. Am. Geriatr. Soc., 50, pp. 1061-1068, (2002)
[7]  
King M.C., Wieand S., Hale K., Et al., Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial, JAMA, 286, pp. 2251-2256, (2001)
[8]  
Powles T.J., The Royal Marsden Hospital (RMH) trial: Key points and remaining questions, Ann. N. Y. Acad. Sci., 949, pp. 109-112, (2001)
[9]  
Veronesi U., Maisonneuve P., Rotmensz N., Et al., Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women, J. Natl. Cancer Inst., 95, pp. 160-165, (2003)
[10]  
Cuzick J., Forbes J., Edwards R., Et al., First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial, Lancet, 360, pp. 817-824, (2002)